Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

PureTech (PRTC)

Price 142.00p on 21-02-2025 at 17:30:01
Change -4.00p -2.74%
Buy 145.00p
Sell 142.00p
Buy / Sell PRTC Shares
Last Trade: Sell 128,804.00 at 142.00p
Day's Volume: 469,388
Last Close: 142.00p
Open: 147.80p
ISIN: GB00BY2Z0H74
Day's Range 142.00p - 147.80p
52wk Range: 132.80p - 238.50p
Market Capitalisation: £340m
VWAP: 143.81503p
Shares in Issue: 239m

Recent Trades History PureTech (PRTC)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 128,804 142.00p Uncrossing Trade
16:35:05 - 21-Feb-25
Sell* 313 142.00p Automatic Execution
16:29:36 - 21-Feb-25
Buy* 552 142.80p Automatic Execution
16:29:31 - 21-Feb-25
Buy* 202 142.40p SI Trade
16:23:30 - 21-Feb-25
Buy* 556 142.40p Automatic Execution
16:22:45 - 21-Feb-25
Buy* 358 142.40p Automatic Execution
16:22:45 - 21-Feb-25
Buy* 1,021 142.40p Automatic Execution
16:22:45 - 21-Feb-25
Buy* 916 142.40p Automatic Execution
16:22:45 - 21-Feb-25
Sell* 556 142.00p Automatic Execution
16:22:45 - 21-Feb-25
Sell* 123 142.40p Automatic Execution
16:21:08 - 21-Feb-25

Share Price History for PureTech

Time period:
to
Date Open High Low Close Volume

Share News for PureTech

PureTech receives FDA fast track designation for leukemia treatment

9th Jan 2025 12:26

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia. Read More

IN BRIEF: PureTech Health says LYT-100 slows lung function decline

16th Dec 2024 14:35

PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Notes that deupirfenidone, also known as LYT-100, slows lung function decline in people with idiopathic pulmonary fibrosis as measured by forced vital capacity in a phase 2b trial. Toby Maher, professor of medicine & director of interstitial lung disease at Keck School of Medicine at the University of Southern California in Los Angeles, and lead investigator in the Elevate IPF trial, says: "Deupirfenidone has the potential to offer patients a highly effective and tolerable treatment option. These are extremely exciting results from a phase 2b trial, and I am very enthusiastic about the continued development of deupirfenidone." Read More

LONDON BRIEFING: Vodafone-Three deal green lit; Shell and Equinor team

5th Dec 2024 07:59

(Alliance News) - London's FTSE 100 is called to open slightly lower on Thursday, despite US stocks spiking to record highs overnight. Read More

TOP NEWS: Retail pair and under-pressure Vistry booted out of FTSE 100

4th Dec 2024 18:15

(Alliance News) - Frasers Group PLC has been relegated from the FTSE 100 index in its latest quarterly shuffle alongside two constituent peers, housebuilder Vistry Group PLC and variety goods retailer B&M European Value Retail SA. Read More

PureTech Health investigates IPF disease burden amid treatment testing

9th Oct 2024 10:03

(Alliance News) - PureTech Health PLC on Wednesday said a new patient survey for people with idiopathic pulmonary fibrosis has provided new insights into disease burden and patient experience. Read More

FTSE 100 Latest
Value8,659.37
Change-3.60

Login to your account

Forgot Password?

Not Registered